Nothing Special   »   [go: up one dir, main page]

EA200300048A1 - Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу - Google Patents

Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу

Info

Publication number
EA200300048A1
EA200300048A1 EA200300048A EA200300048A EA200300048A1 EA 200300048 A1 EA200300048 A1 EA 200300048A1 EA 200300048 A EA200300048 A EA 200300048A EA 200300048 A EA200300048 A EA 200300048A EA 200300048 A1 EA200300048 A1 EA 200300048A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharnesiltransferase
hinazoline
annelied
enantiomer
inhibiting
Prior art date
Application number
EA200300048A
Other languages
English (en)
Other versions
EA005065B1 (ru
Inventor
Марк Гастон Вене
Патрик Рене Анжибо
Дэвид Вилльям Энд
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200300048A1 publication Critical patent/EA200300048A1/ru
Publication of EA005065B1 publication Critical patent/EA005065B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к (-)-5-(3-хлорфенил)-α-(4-хлорфенил)-α-(1-метил-1Н-имидазол-5-ил)тетразоло[1,5-а]хиназолин-7-метанамину и его фармацевтически приемлемым кислотно-аддитивным солям, использованию данных соединений в медицине, главным образом, для лечения раковых заболеваний.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300048A 2000-06-22 2001-06-13 Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу EA005065B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (2)

Publication Number Publication Date
EA200300048A1 true EA200300048A1 (ru) 2003-04-24
EA005065B1 EA005065B1 (ru) 2004-10-28

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300048A EA005065B1 (ru) 2000-06-22 2001-06-13 Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу

Country Status (34)

Country Link
US (3) US20030114471A1 (ru)
EP (1) EP1296984B1 (ru)
JP (1) JP4919575B2 (ru)
KR (2) KR100831940B1 (ru)
CN (1) CN1207296C (ru)
AR (1) AR030704A1 (ru)
AT (1) ATE294804T1 (ru)
AU (3) AU6396201A (ru)
BG (1) BG65894B1 (ru)
BR (1) BRPI0111743B8 (ru)
CA (1) CA2410232C (ru)
CZ (1) CZ295278B6 (ru)
DE (1) DE60110592T2 (ru)
EA (1) EA005065B1 (ru)
EE (1) EE04966B1 (ru)
EG (1) EG24180A (ru)
ES (1) ES2241830T3 (ru)
HK (1) HK1058363A1 (ru)
HR (1) HRP20020989B1 (ru)
HU (1) HU229095B1 (ru)
IL (2) IL153560A0 (ru)
IS (1) IS2596B (ru)
JO (1) JO2361B1 (ru)
MX (1) MXPA02012845A (ru)
MY (1) MY127734A (ru)
NO (1) NO324494B1 (ru)
NZ (1) NZ522481A (ru)
PA (1) PA8519501A1 (ru)
PL (1) PL209521B1 (ru)
SA (1) SA01220349B1 (ru)
SK (1) SK285699B6 (ru)
UA (1) UA73572C2 (ru)
WO (1) WO2001098302A1 (ru)
ZA (1) ZA200210305B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
JP4384505B2 (ja) 2002-04-15 2009-12-16 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する炭素連結イミダゾールもしくはトリアゾール置換三環状キナゾリン誘導体
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3285768B1 (en) 2015-04-21 2020-12-30 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
TWI710642B (zh) 2015-08-17 2020-11-21 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（farnesyltransferase）抑制劑治療癌症病患之方法
HUE053927T2 (hu) 2016-11-03 2021-07-28 Kura Oncology Inc Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
EA000710B1 (ru) * 1995-12-08 2000-02-28 Жансен Фармасетика Н.В. (имидазол-5-ил)метил-2-хинолиноновые производные, ингибирующие фарнезилпротеин-трансферазу
WO1997036876A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
DK0988038T3 (da) 1997-06-02 2002-12-02 Janssen Pharmaceutica Nv Anvendelse af (imidazol-5-yl)methyl-2-quinolinon derivater til hæmning af glat muskelcelleproliferation
CA2337800C (en) 1998-07-06 2007-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
IL140721A0 (en) * 1998-07-06 2002-02-10 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
EA200100135A1 (ru) * 1998-08-27 2001-08-27 Пфайзер Продактс Инк. Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
EE04962B1 (et) * 1998-12-23 2008-02-15 Janssen Pharmaceutica N.V. Kinoliini ühend, seda sisaldav farmatseutiline kompositsioon, ühendi kasutamine ravimina ning meetod ühendi ja kompositsiooni valmistamiseks
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
JP4090200B2 (ja) * 1999-02-11 2008-05-28 ファイザー・プロダクツ・インク 抗癌薬として有用なヘテロアリール置換キノリン−２−オン誘導体
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
AU2001293835A1 (en) 2000-09-25 2002-04-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
DE60135919D1 (de) 2000-09-25 2008-11-06 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate

Also Published As

Publication number Publication date
EP1296984A1 (en) 2003-04-02
SK502003A3 (en) 2003-05-02
SA01220349B1 (ar) 2007-01-23
EP1296984B1 (en) 2005-05-04
US8329714B2 (en) 2012-12-11
AR030704A1 (es) 2003-09-03
HUP0300872A3 (en) 2004-11-29
JO2361B1 (en) 2006-12-12
AU2001263962B2 (en) 2006-07-20
DE60110592T2 (de) 2006-01-19
WO2001098302A1 (en) 2001-12-27
CA2410232A1 (en) 2001-12-27
AU6396201A (en) 2002-01-02
NO324494B1 (no) 2007-10-29
CA2410232C (en) 2008-10-07
HRP20020989A2 (en) 2005-02-28
PA8519501A1 (es) 2002-08-29
EG24180A (en) 2008-09-28
NO20026032L (no) 2002-12-16
KR100846370B1 (ko) 2008-07-15
HRP20020989B1 (en) 2011-05-31
JP2004501153A (ja) 2004-01-15
EA005065B1 (ru) 2004-10-28
BG107310A (bg) 2003-07-31
AU2006220405B2 (en) 2009-05-21
BG65894B1 (bg) 2010-04-30
IS2596B (is) 2010-03-15
ATE294804T1 (de) 2005-05-15
HK1058363A1 (en) 2004-05-14
MXPA02012845A (es) 2003-05-15
JP4919575B2 (ja) 2012-04-18
KR20070121847A (ko) 2007-12-27
KR20030009463A (ko) 2003-01-29
NZ522481A (en) 2004-09-24
US20030114471A1 (en) 2003-06-19
CN1437601A (zh) 2003-08-20
BRPI0111743B8 (pt) 2021-05-25
MY127734A (en) 2006-12-29
NO20026032D0 (no) 2002-12-16
HU229095B1 (en) 2013-07-29
ZA200210305B (en) 2004-03-19
HUP0300872A2 (hu) 2003-07-28
ES2241830T3 (es) 2005-11-01
PL358918A1 (en) 2004-08-23
IL153560A0 (en) 2003-07-06
DE60110592D1 (de) 2005-06-09
CN1207296C (zh) 2005-06-22
CZ295278B6 (cs) 2005-06-15
EE200200695A (et) 2004-06-15
US20080114009A1 (en) 2008-05-15
IS6590A (is) 2002-10-25
SK285699B6 (sk) 2007-06-07
IL153560A (en) 2011-06-30
US8318753B2 (en) 2012-11-27
US20070259902A1 (en) 2007-11-08
UA73572C2 (en) 2005-08-15
KR100831940B1 (ko) 2008-05-23
AU2006220405A1 (en) 2006-10-12
CZ2003114A3 (cs) 2003-05-14
PL209521B1 (pl) 2011-09-30
BRPI0111743B1 (pt) 2019-03-26
BR0111743A (pt) 2003-07-08
EE04966B1 (et) 2008-02-15

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
MY133667A (en) Quinazoline ditosylate salt compounds
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
EA200100764A1 (ru) Трициклические ингибиторы поли(adp-рибозо) полимераз
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
WO2001039763A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
TNSN03144A1 (en) Pyrrolopyrimidines as protein kinase inhibitors
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
IL182893A0 (en) PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
EA200001043A2 (ru) Соединения для лечения женской сексуальной дисфункции
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
GB0112348D0 (en) Compounds
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
MY129635A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
EP0725641A4 (ru)
EA200300048A1 (ru) Энантиомер 1,2-аннелированного хиназолина, ингибирующий фарнезилтрансферазу
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
SE9902267D0 (sv) New compounds
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
WO2001007029A3 (en) Substituted guanidines and the use thereof
ATE296631T1 (de) Verwendung von pde5 inhibitoren zur behandlung vorzeitiger ejakulation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MK4A Patent expired

Designated state(s): KZ RU